keyword
https://read.qxmd.com/read/38267764/-hemophagocytic-lymphohistiocytosis-and-macrophage-activation-syndrome-a-multidisciplinary-challenge
#21
REVIEW
Nikolas Ruffer, Ricardo Kosch, Katja Weisel, Ina Kötter, Martin Krusche
Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome that is characterized by hyperferritinemia, cytopenia, disseminated intravascular coagulopathy and functional disorders of the liver and the central nervous system. The term macrophage activation syndrome is predominantly used for secondary HLH in the context of autoimmune diseases (e.g., systemic juvenile idiopathic arthritis). In addition, malignancies and genetic inborn errors of immunity can predispose to the development of HLH...
January 24, 2024: Zeitschrift Für Rheumatologie
https://read.qxmd.com/read/38224701/low-dose-versus-standard-dose-olanzapine-with-triple-antiemetic-therapy-for-prevention-of-highly-emetogenic-chemotherapy-induced-nausea-and-vomiting-in-patients-with-solid-tumours-a-single-centre-open-label-non-inferiority-randomised-controlled-phase-3-trial
#22
RANDOMIZED CONTROLLED TRIAL
Jyoti Bajpai, Venkatesh Kapu, Sushmita Rath, Sravan Kumar, Anbarasan Sekar, Priyanka Patil, Altaf Siddiqui, Srikanth Anne, Akash Pawar, Sujay Srinivas, Prabhat Bhargava, Seema Gulia, Vanita Noronha, Amit Joshi, Kumar Prabhash, Shripad Banavali, Rajiv Sarin, Rajendra Badwe, Sudeep Gupta
BACKGROUND: Olanzapine is an effective antiemetic agent but it results in substantial daytime somnolence when administered at the standard dose. Our aim was to compare the efficacy of low-dose versus standard-dose olanzapine after highly emetogenic chemotherapy in patients with solid tumours. METHODS: This was a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial done in a tertiary care referral centre in India (Tata Memorial Centre, Homi Bhabha National Institute, Mumbai)...
February 2024: Lancet Oncology
https://read.qxmd.com/read/38184925/-the-last-bridge-how-patients-experience-the-car-t-cell-therapy-a-qualitative-study
#23
JOURNAL ARTICLE
Verena Leinemann, Simon Krutter
PURPOSE: CAR T-cell therapy gives patients new hope, who are diagnosed with relapsed or refractory B-cell lymphoma or B-cell leukaemia. To date, there is no scientific knowledge about the experiences of patients with CAR T-cell therapy, their process of treatment decision making or how they handle potential side effects. The study aims at deepening the understanding of the patient's experiences, indicating how to improve nursing care for this patient population. METHOD: A qualitative study was carried out...
December 22, 2023: European Journal of Oncology Nursing: the Official Journal of European Oncology Nursing Society
https://read.qxmd.com/read/38132380/breakthrough-and-episodic-cancer-pain-from-a-palliative-care-perspective
#24
JOURNAL ARTICLE
Erik Torbjørn Løhre, Gunnhild Jakobsen, Tora Skeidsvoll Solheim, Pål Klepstad, Morten Thronæs
Cancer pain intensity (PI) fluctuates, but the relationship between pain flares and background pain with respect to pain management is not settled. We studied how flare and background PIs corresponded with treatment results for background cancer pain. Patients admitted to an acute palliative care unit with average and/or worst PI ≥ 1 on the 11-point numeric rating scale were included. Average and worst PI at admission and average PI at discharge were collected. We examined how the difference and ratio between worst and average PI and average PI at admission, were associated with average PI development during hospitalization...
November 30, 2023: Current Oncology
https://read.qxmd.com/read/38127868/impact-of-time-to-antibiotic-delivery-in-pediatric-patients-with-cancer-presenting-with-febrile-neutropenia
#25
JOURNAL ARTICLE
George C De Castro, Leonora R Slatnick, Morgan Shannon, Zhiguo Zhao, Kasey Jackson, Christine M Smith, Daniel Whitehurst, Claire Elliott, Chelsea C Clark, Halden F Scott, Debra L Friedman, Jenna Demedis, Adam J Esbenshade
PURPOSE: Febrile neutropenia (FN) in pediatric patients with cancer can cause severe infections, and prompt antibiotics are warranted. Extrapolated from other populations, a time-to-antibiotic (TTA) metric of <60 minutes after medical center presentation was established, with compliance data factoring into pediatric oncology program national rankings. METHODS: All FN episodes occurring at Vanderbilt Children's Hospital (2007-February 2022) and a sample of episodes from Colorado Children's Hospital (2012-2019) were abstracted, capturing TTA and clinical outcomes including major complications (intensive care unit [ICU] admission, vasopressors, intubation, or infection-related mortality)...
December 21, 2023: JCO oncology practice
https://read.qxmd.com/read/38060973/prospective-external-validation-of-the-esbenshade-vanderbilt-models-accurately-predicts-bloodstream-infection-risk-in-febrile-non-neutropenic-children-with-cancer
#26
JOURNAL ARTICLE
Zhiguo Zhao, Pratik A Patel, Leonora Slatnick, Anna Sitthi-Amorn, Kevin J Bielamowicz, Farranaz A Nunez, Alexandria M Walsh, Jennifer Hess, Jenna Rossoff, Caitlin Elgarten, Regina Myers, Raya Saab, Maya Basbous, Meghan Mccormick, Catherine Aftandilian, Rebecca Richards, C Nathan Nessle, Alison C Tribble, Jessica K Sheth Bhutada, Scott L Coven, Daniel Runco, Jennifer Wilkes, Arun Gurunathan, Terri Guinipero, Jennifer A Belsky, Karen Lee, Victor Wong, Megha Malhotra, Amy Armstrong, Lauren P Jerkins, Shane J Cross, Lyndsay Fisher, Madison T Stein, Natalie L Wu, Troy Yi, Etan Orgel, Gabrielle M Haeusler, Joshua Wolf, Jenna M Demedis, Tamara P Miller, Adam J Esbenshade
PURPOSE: The optimal management of fever without severe neutropenia (absolute neutrophil count [ANC] ≥500/µL) in pediatric patients with cancer is undefined. The previously proposed Esbenshade Vanderbilt (EsVan) models accurately predict bacterial bloodstream infections (BSIs) in this population and provide risk stratification to aid management, but have lacked prospective external validation. MATERIALS AND METHODS: Episodes of fever with a central venous catheter and ANC ≥500/µL occurring in pediatric patients with cancer were prospectively collected from 18 academic medical centers...
March 1, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38028041/a-rare-cause-of-posterior-reversible-encephalopathy-syndrome-acute-lymphoblastic-leukemia
#27
Jessica Hayes, Anne Byrd Mahoney, Claci Ayers, Asha Sarma, Kevin C Ess, Tracy E Hunley, Christine Moore Smith
KEY CLINICAL MESSAGE: The presentation of posterior reversible encephalopathy syndrome (PRES) as the initial presenting sign of acute lymphoblastic leukemia is unusual, as PRES is more often a complication of therapy. This case highlights the importance of maintaining a broad differential diagnosis for pediatric hypertension and its complications. ABSTRACT: A 6-year-old male presented with a seizure-like episode. Evaluation revealed hypertension and brain imaging showed findings consistent with posterior reversible encephalopathy syndrome...
November 2023: Clinical Case Reports
https://read.qxmd.com/read/38023197/case-report-blinatumomab-as-upfront-consolidation-and-maintenance-therapy-in-a-pediatric-patient-with-high-risk-b-cell-acute-lymphoblastic-leukemia
#28
Sumit Gupta, Jessica Casey, Joseph Lasky
INTRODUCTION: B-cell acute lymphoblastic leukemia (B-ALL) is the most common malignancy in children. The current conventional chemotherapy regimens have high overall survival but with significant short- and long-term toxicities, sometimes requiring delay and termination of chemotherapy. Bispecific T-cell engager antibody blinatumomab has been successful in achieving bone marrow remission and acting as bridging therapy in minimal residual disease (MRD)-positive relapsed adult and pediatric B-ALL patients...
2023: Frontiers in Oncology
https://read.qxmd.com/read/38019890/parent-and-clinician-perceptions-and-recommendations-on-a-pediatric-cancer-pain-management-app-a-qualitative-co-design-study
#29
JOURNAL ARTICLE
Lindsay A Jibb, Surabhi Sivaratnam, Elham Hashemi, Charlene H Chu, Paul C Nathan, Julie Chartrand, Nicole M Alberts, Tatenda Masama, Hannah G Pease, Lessley B Torres, Haydee G Cortes, Mallory Zworth, Susan Kuczynski, Michelle A Fortier
Pain is one of the most prevalent and burdensome pediatric cancer symptoms for young children and their families. A significant proportion of pain episodes are experienced in environments where management options are limited, including at home. Digital innovations such as apps may have positive impacts on pain outcomes for young children in these environments. Our overall aim is to co-design such an app and the objective of this study was to explore the perceptions of children's parents about app utility, needed system features, and challenges...
November 2023: PLOS Digit Health
https://read.qxmd.com/read/37983368/central-venous-catheter-related-bloodstream-infections-caused-by-enterobacterales-in-pediatric-oncology-patients-catheter-salvage-or-removal
#30
JOURNAL ARTICLE
Ceder H van den Bosch, Aranka L Kops, Yvette G T Loeffen, Alida F W van der Steeg, Marianne D van de Wetering, Marta F Fiocco, Miquel B Ekkelenkamp, Tom F W Wolfs
BACKGROUND: The aim was to determine whether salvage treatment with systemic antibiotics is a safe and effective strategy for Enterobacterales bloodstream infections (BSI) in pediatric oncology patients with a central venous catheter (CVC). METHODS: A retrospective study was performed on oncology and stem cell recipient patients with a CVC and blood culture with Enterobacterales, at the Princess Máxima Centre for Pediatric Oncology, Utrecht, the Netherlands...
November 16, 2023: Pediatric Infectious Disease Journal
https://read.qxmd.com/read/37978356/symptom-and-problem-clusters-in-german-specialist-palliative-home-care-a-factor-analysis-of-non-oncological-and-oncological-patients-symptom-burden
#31
JOURNAL ARTICLE
Daniela Gesell, Farina Hodiamont, Julia Wikert, Eva Lehmann-Emele, Claudia Bausewein, Friedemann Nauck, Maximiliane Jansky
BACKGROUND: Specialist palliative home care (SPHC) aims to maintain and improve patients' quality of life in the community setting. Symptom burden may differ between oncological and non-oncological patients. However, little is known about diagnosis-related differences of SPHC patients. This study aims to describe the prevalence of physical symptom burden and psychosocial problems of adult patients in SPHC, and to evaluate diagnosis-related symptom clusters. METHODS: Secondary analysis of data from a prospective, cross-sectional, multi-centre study on complexity of patients, registered at the German Register for Clinical Studies (DRKS trial registration number: DRKS00020517, 12/10/2020)...
November 17, 2023: BMC Palliative Care
https://read.qxmd.com/read/37957523/the-impact-of-biosimilar-use-on-total-cost-of-care-and-provider-financial-performance-in-the-medicare-oncology-care-model-a-population-based-simulation-study
#32
JOURNAL ARTICLE
Jingyan Yang, Basit I Chaudhry, Andrew T Yue, Joshua A Roth, John M Kelton, Ahmed Shelbaya, Lisa Tran, Meng Li
INTRODUCTION: Payment for oncology care is increasingly moving from fee-for-service to value-based payment (VBP). VBPs are agreements in which providers are held accountable for total cost of care (TCOC) through risk-sharing arrangements with payers that tie reimbursement levels to TCOC benchmarks. Oncology biosimilars may play an important role in managing financial risk in the VBPs like Medicare's Oncology Care Model (OCM), but there has been limited research in this area. The objective of this study is to estimate the impact of biosimilar adoption on TCOC and oncology provider financial performance under the terms of the Medicare OCM...
November 14, 2023: Advances in Therapy
https://read.qxmd.com/read/37953218/impact-of-mandated-drug-monitoring-on-opioid-use-during-highly-conformal-radiotherapy-for-oropharynx-cancer
#33
JOURNAL ARTICLE
Jayden Gracie, Adam L Holtzman, Roi Dagan, Curtis M Bryant, Christopher G Morris, William M Mendenhall
BACKGROUND: Prescription drug monitoring programs (PDMPs) have proliferated due to increasing opioid-related deaths. We evaluated acute opioid use changes for 64 patients treated with highly conformal radiotherapy (RT) following a state-mandated PDMP. METHODS: Patients receiving proton therapy (PT) (n=40), intensity-modulated RT (IMRT) (n=14), or both (n=10) were divided into preintervention (n=26) and postintervention cohorts (n=38); records were reviewed retrospectively under an institutional review board (IRB)-approved tracking protocol...
October 27, 2023: Annals of Palliative Medicine
https://read.qxmd.com/read/37948645/impact-of-including-drug-spending-in-oncology-alternative-payment-models
#34
JOURNAL ARTICLE
Luca Maini, Jacob P Klimek, David C Johnson, George M Holmes, Darren A DeWalt
OBJECTIVES: To develop a method for determining the effect of including drug costs in alternative payment models (APMs). STUDY DESIGN: Retrospective claims analysis. METHODS: Using the Oncology Care Model as an example, we developed an oncology episode payment model for a commercial payer using historical claims data. We defined 6-month episodes of chemotherapy. Using claims data, we characterized episodes and developed a risk adjustment model...
November 2023: American Journal of Managed Care
https://read.qxmd.com/read/37900520/the-characteristics-and-follow-up-of-sars-cov-2-infection-in-pediatric-oncology-patients
#35
JOURNAL ARTICLE
Raghad Alkharouby, Noura Aljehani, Nasser Alsubaie, Anas Alqarni, Mohammed Hariri, Naglla Elimam, Baraa AlhajHussein, Aeshah A AlAzmi
Introduction Clinical data about the first and second most prominent waves of SARS-CoV-2 among pediatric cancer patients were inconsistent. This study aims to retrospectively report the clinical characteristics and outcomes of SARS-CoV-2 infection in pediatric oncology patients. Methods This is an observational, retrospective study conducted in a tertiary care oncology center from March 2020 to May 2022. We reviewed the prevalence, severity of symptoms, and duration of positivity in relation to blood count laboratory data and mortality with a follow-up of 30 days post-infection for SARS-CoV-2...
September 2023: Curēus
https://read.qxmd.com/read/37900376/peritoneal-carcinoma-unveiling-a-hidden-threat-a-case-of-malignant-pericardial-effusion
#36
Mohammed Abusuliman, Amr M Mohamed, Anas Mahmoud, Tala Beliani, Ibrahim M Ismail-Sayed
Malignant pericardial effusion (MPE) is a slowly progressive and potentially clinically silent condition. Pericardial effusion can arise in oncology patients due to several factors, including disease spreading directly or metastatically, anticancer therapy side effects, or both. Solid and hematological malignancy metastasis more frequently involves the pericardium than primary tumors, with lung cancer being the most common metastatic tumor to involve the pericardium. While 5%-20% of all patients with metastatic neoplasms have pericardial involvement, MPE rarely appears with hemodynamic instability...
September 2023: Curēus
https://read.qxmd.com/read/37828258/a-prospective-real-world-multinational-study-of-febrile-neutropenia-fn-occurrence-in-oncology-patients-receiving-chemotherapy-with-intermediate-risk-of-fn-a-mascc-neutropenia-infection-and-myelosuppression-study-group-initiative
#37
MULTICENTER STUDY
Bernardo Leon Rapoport, Marcial Garcia-Morillo, Carme Font, Zarka Samoon, Adnan Abdul Jabbar, Hampig Raphael Kourie, Aline Kayumba, Francis Esposito, Razvan Andrei Popescu, Jesus García-Gómez, Liezl Heyman, Teresa Smit, Andriy Krendyukov, Nicola Mathieson, Tim Cooksley, Ronald Anderson, Jean Klastersky
PURPOSE: Limited knowledge is available on the incidence of febrile neutropenia (FN) in intermediate-risk patients and the rationale for use of granulocyte colony-stimulating factor (G-CSF) in these patients. We aimed to estimate the rate at which patients associated with intermediate risk (10-20%) of FN would develop ≥ 1 episode of FN with a commonly used chemotherapy regimen in clinical practice. METHODS: This prospective, real-world, observational, multinational, multicenter study (December 2016-October 2019) recruited patients with solid tumors or Hodgkin's/non-Hodgkin's lymphoma...
October 13, 2023: Supportive Care in Cancer
https://read.qxmd.com/read/37784827/stereotactic-cardiac-ablative-radiotherapy-scar-for-refractory-ventricular-tachycardia-western-australia-experience
#38
JOURNAL ARTICLE
T S Lim, H P Kirupananther, S Goodall, B King
PURPOSE/OBJECTIVE(S): Ventricular tachycardia is a potentially life-threatening cardiac condition that is associated with significant morbidity and mortality. Despite advances in medical therapies, implantable cardioverter-defibrillator (ICD) and catheter ablative therapy (CAT), some patients continue to suffer recurrent VT. SCAR is a highly accurate, non-invasive, and novel ablative therapeutic option that has shown promising results in the treatment of refractory VT patients associated with structural heart disease...
October 1, 2023: International Journal of Radiation Oncology, Biology, Physics
https://read.qxmd.com/read/37784604/comparing-changes-in-medicare-reimbursement-for-radiation-oncology-and-medical-oncology-2010-2020
#39
JOURNAL ARTICLE
J S Hogan, J C Baumann, B W Fischer-Valuck, C A Perez, J M Michalski, P Karraker, N Vapiwala, M P Mehta, J D Bradley, B C Baumann
PURPOSE/OBJECTIVE(S): A recent study found that radiation oncology (RO) has seen significant declines in Medicare reimbursement (MCR) from 2010-2019. While it is presumed that other cancer subspecialties have seen decreasing MCR, to our knowledge, there are no studies directly comparing changes in MCR between RO and other oncology subspecialties. In this study, we analyze changes in MCR from 2010-2020 for both RO and medical oncology. We hypothesized that the declines in MCR will be similar between the two fields...
October 1, 2023: International Journal of Radiation Oncology, Biology, Physics
https://read.qxmd.com/read/37748366/status-epilepticus-in-patients-with-glioblastoma-clinical-characteristics-risk-factors-and-epileptological-outcome
#40
JOURNAL ARTICLE
Jenny Stritzelberger, Anna Gesmann, Imke Fuhrmann, Stefanie Balk, Caroline Reindl, Dominik Madžar, Martin Uhl, Tamara M Welte, Sebastian Brandner, Felix Eisenhut, Arnd Dörfler, Roland Coras, Werner Adler, Stefan Schwab, Florian Putz, Rainer Fietkau, Luitpold Distel, Hajo M Hamer
PURPOSE: Epilepsy is a common comorbidity in patients with glioblastoma, however, clinical data on status epilepticus (SE) in these patients is sparse. We aimed to investigate the risk factors associated with the occurrence and adverse outcomes of SE in glioblastoma patients. METHODS: We retrospectively analysed electronic medical records of patients with de-novo glioblastoma treated at our institution between 01/2006 and 01/2020 and collected data on patient, tumour, and SE characteristics...
November 2023: Seizure: the Journal of the British Epilepsy Association
keyword
keyword
32667
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.